Loading
HKSEHealthcareBiotechnology
Latest quote
HK$74.40
−HK$2.85 · -3.69%
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Latest quote
HK$74.40
−HK$2.85 · -3.69%
Regular session · HKT · Market data may be delayed.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Day range
Current HK$74.40
52-week range
Current HK$74.40
Regular session · HKT · Market data may be delayed.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Day range
Current HK$74.40
52-week range
Current HK$74.40
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.24B CNY | 1.72B CNY | 1.08B CNY | 767.78M CNY | 1.42B CNY |
| Cost of goods sold | 415.49M CNY | 346.72M CNY | 253.14M CNY | 269.94M CNY | 67.16M CNY |
| Gross profit | 2.84B CNY | 1.37B CNY | 822.99M CNY | 497.84M CNY | 1.36B CNY |
| Research and development | 1.08B CNY | 1.56B CNY | 1.31B CNY | 982.08M CNY | 710.97M CNY |
| Selling, general, and administrative | 1.48B CNY | 1.28B CNY | 1.09B CNY | 713.24M CNY | 482.81M CNY |
| Operating expenses | 2.11B CNY | 2.83B CNY | 2.33B CNY | 1.55B CNY | 1.05B CNY |
| Interest income | 4.89M CNY | 10.24M CNY | 28.14M CNY | 61.54M CNY | 43.35M CNY |
| Interest expense | 68.53M CNY | 72.38M CNY | 23.09M CNY | 6.76M CNY | 5.32M CNY |
| Depreciation and amortization | 312.05M CNY | 231.01M CNY | 240.28M CNY | 186.37M CNY | 120.47M CNY |
| Operating income | 156.35M CNY | −1.46B CNY | −1.5B CNY | −1.05B CNY | 162.84M CNY |
| Net income | 709.65M CNY | −1.47B CNY | −1.51B CNY | −997.84M CNY | 276.26M CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS27.82M0.00%646.2B USD0.05%$86.45-1.10%
Vanguard FTSE Emerging Markets ETFVWO27.71M0.02%162.3B USD0.06%$60.095-1.27%
iShares Core MSCI Emerging Markets ETFIEMG21.6M0.01%163.85B USD0.09%$81.82-1.72%
iShares Core MSCI China ETF2801.HK9.16M0.07%12.38B HKD0.20%HK$23.84-1.57%
iShares Core MSCI Asia ex Japan ETF3010.HK5.79M0.02%35.89B HKD0.28%HK$91.34-1.02%
iShares Core MSCI Asia ex Japan ETF83010.HK4.95M0.02%30.72B CNY0.28%CN¥78.42-0.48%
iShares MSCI Emerging Markets ETFEEM4.61M0.01%31.76B USD0.72%$67.195-1.88%
iShares MSCI China ETFMCHI4.53M0.07%6.32B USD0.59%$52.955-0.72%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGiShares Core MSCI China ETF2801.HKiShares Core MSCI Asia ex Japan ETF3010.HKiShares Core MSCI Asia ex Japan ETF83010.HKiShares MSCI Emerging Markets ETFEEMiShares MSCI China ETFMCHIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
